|
Jul 28
|
Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD
|
|
Jul 28
|
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
|
|
Jul 28
|
Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap
|
|
Jul 28
|
Healthcare earnings: UnitedHealth delays, Sarepta's FDA probe
|
|
Jul 28
|
Sarepta Therapeutics Could Face Financial Trouble by 2027 if Elevidys Does Not Return to Market by Early 2026, RBC Says
|
|
Jul 28
|
BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50
|
|
Jul 28
|
Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.
|
|
Jul 28
|
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
|
|
Jul 28
|
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
|
|
Jul 25
|
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
|
|
Jul 25
|
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
|
|
Jul 25
|
CHMP rejects Elevidys in latest setback for Sarepta
|
|
Jul 25
|
Solid Corporate Earnings Results Support Stocks
|
|
Jul 25
|
Stock Market Today: S&P 500 Notches Fifth Consecutive Record Close as Vanguard, Goldman Warn On Growth
|
|
Jul 25
|
Update: Market Chatter: FDA Unlikely to Clear Sarepta's Gene Therapy Elevidys Without New Safety Data
|
|
Jul 25
|
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
|
|
Jul 25
|
Sarepta stock falls after Elevidys fails to get backing by EU regulators
|
|
Jul 25
|
Sarepta woes mount as Duchenne gene therapy knocked back in Europe
|
|
Jul 24
|
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'
|
|
Jul 24
|
Sector Update: Health Care Stocks Softer in Afternoon Trading
|